初发2型糖尿病患者应用沙格列汀与长秀霖的临床探讨  

Clinical Study of Saxagliptin and Changxiulin in Newly Diagnosed Type 2 Diabetic Patients

作　　者：王孝男 WANG Xiaonan(Department of Internal Medicine,Taishan People's Hospital,Tai'an,Shandong Province,271038 China)

机构地区：[1]泰安市泰山区人民医院内科,山东泰安271038

出　　处：《世界复合医学》2021年第4期140-142,共3页World Journal of Complex Medicine

摘　　要：目的分析初发2型糖尿病患者应用沙格列汀与长秀霖的临床效益。方法选取2019年1月—2020年6月期间该院收治的60例初发2型糖尿病患者为研究对象,根据随机动态数字表分别以对照组、研究组进行归纳,每组30例。对照组实施长秀霖治疗方案,研究组实施长秀霖联合沙格列汀治疗方案;对比两组患者治疗总有效率、治疗前后血糖水平以及血糖达标时间、胰岛素用量、低血糖发生率。结果研究组总有效率(96.67%)、低血糖率(3.33%)相优于对照组(73.33%、23.33%),差异有统计学意义(χ^(2)=4.709、5.192,P<0.05);经治疗研究组患者的FPG (5.18±0.46)mmol/L、2 hPG (8.06±0.90)mmol/L、HbA1c (6.56±0.53)%、血糖达标时间(4.25±1.47)d、胰岛素用量(43.18±8.63)IU/d明显低于对照组,差异有统计学意义(t=9.971、7.049、3.534、10.012、3.815,P<0.05)。结论初发2型糖尿病患者应用沙格列汀与长秀霖可以减少胰岛素使用剂量,并在短时间内改善患者的血糖指标,患者出现低血糖的风险性较低,值得作为推广方案。Objective To analyze the clinical benefits of saxagliptin and Changxiulin in patients with newly diagnosed type 2 diabetes.Methods Sixty patients with newly diagnosed type 2 diabetes who were admitted to the hospital from January 2019 to June 2020 were selected as the research objects.According to the random dynamic number table,the control group and the study group were respectively summarized,with 30 cases in each group.The control group implemented the Changxiulin treatment plan,and the study group implemented the Changxiulin combined saxagliptin treatment plan;the total effective rate of treatment,blood glucose levels before and after treatment,blood glucose reaching standard time,insulin dosage,and incidence of hypoglycemia were compared between the two groups.Results The total effective rate(96.67%)and hypoglycemia rate(3.33%)of the study group were better than those of the control group(73.33%and 23.33%),and the difference was statistically significant(χ^(2)=4.709,5.192,P<0.05);after treatment in the study group of patient’s FPG(5.18±0.46)mmol/L,2 hPG(8.06±0.90)mmol/L,HbA1c(6.56±0.53)%,blood glucose compliance time(4.25±1.47)d,insulin dosage(43.18±8.63)IU/L d were significantly lower than the control group,and the difference was statistically significant(t=9.971,7.049,3.534,10.012,3.815,P<0.05).Conclusion The use of saxagliptin and Changxiulin in patients with newly-onset type 2 diabetes can reduce the dosage of insulin and improve the blood glucose index of the patients in a short time.The risk of hypoglycemia in patients is low,and it is worthy of promotion.

关 键 词：初发2型糖尿病 长秀霖 沙格列汀 低血糖发生率 

分 类 号：R587.1[医药卫生—内分泌]